BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB Learn More >
Patients First

Patients First

Individuals living with serious and debilitating chronic conditions often struggle with feelings of isolation. Because the effects are often individualized to the patient, the impact can easily be misunderstood or minimized by society—leaving patients feeling abandoned and alone. This is especially true for the more than 20 million individuals living with chronic, severe pain in the United States.

At BDSI, our mission extends beyond providing access to therapeutic solutions. We believe advocating for patients—being a voice for awareness and change—is an integral part of helping individuals make progress in their lives. This is who we are.

Image of woman

"If you could see my pain, you would see the beautiful mask of my face, and under it, you would see every natural disaster happening at the same time."

"You can't judge a person just by looking at them. On the outside, they may look very normal and healthy, but on the inside, they may be experiencing a constant firestorm of pain."

Image of man

Recent BDSI News

September 9, 2021

Expands Portfolio and Establishes Growth Platform in Neurology The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Commercial Launch Planned for Q1 2022 Investor Day on October 14, 2021 RALEIGH, N.C. , Sept.

Read more
September 7, 2021

RALEIGH, N.C. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding BELBUCA ®  (buprenorphine buccal film), CIII

Read more
September 3, 2021

RALEIGH, N.C. , Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Chief Executive Officer, and

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
September 28, 2021BDSI $3.66/ - -2.14%
Data provided by Nasdaq. Minimum 15 minutes delayed.